Discover real-time bio-protocol prices and start trading on BingX. Whether you're a newbie or an experienced investor, enjoy a seamless crypto experience with exclusive welcome rewards for new users.

How do you feel about Bio Protocol (BIO) today?

Bullish

50%

Bearish

50%

Bio Protocol (BIO) Price Today

The live price of Bio Protocol is 0.04 USD. In the past 24 hours, the trading volume of Bio Protocol was 21,858,767.56 USD, down by -6.07%. The current price has decreased by -18.76% from its 7-day high of 0.88 USD, and increased by 0.04% from its 7-day low of 0.04 USD. With a circulating supply of 3,320,000,000.00 Bio Protocol, the market cap of Bio Protocol is currently 340,212,467.00 USD, down by 0% in the last 24 hours. Bio Protocol currently ranks #464 by market capitalization among cryptocurrencies.

Bio Protocol (BIO) Market Data

Market Cap

$88.3M

24h Volume

$21.8M

Circulating Supply

1.7B BIO

Maximum Supply

3.3B BIO

Fully Diluted Market Cap

$165.7M

Liquidity Indicator

24.74%

About Bio Protocol (BIO)

How can I buy Bio Protocol (BIO)?

Buying Bio Protocol (BIO) on BingX is simple and secure. Create an account, deposit USDT or another supported asset, and purchase Bio Protocol (BIO) directly in the Spot Market. The tokens will then appear in your BingX Spot Wallet, ready for trading or transfer at anytime. Discover How to Buy BIO Guide for more information.

What Is Bio Protocol (BIO) and How Does It Work?

Bio Protocol is a decentralized science infrastructure that empowers researchers, patients, and biotech projects by building on-chain BioDAOs, decentralized biotech organizations that manage funding, intellectual property, and scientific research democratically. The platform uses BIO as its native token to align incentives. Users stake BIO to vote on which BioDAOs receive funding, to curate promising research proposals, and to contribute to IP commercialization decisions. In addition, Bio Protocol deploys BioAgents, autonomous on-chain agents that can perform scientific tasks like hypothesis generation, data analysis, and milestone verification, automating parts of the biotech workflow. This structure allows the community to pool capital, reward meaningful scientific contributions, and govern biotech IP in a transparent, decentralized way. By connecting financial incentives with real-world research, Bio Protocol is trying to make scientific funding more equitable and efficient.

When Did BIO Launch?

Bio Protocol and its native token BIO launched in March 2025, developed by CEO Juan Martinez and CTO Sophia Chen. At launch, users could participate in BioDAO governance, stake BIO to vote on funding proposals, and engage with the BioAgent system that automates scientific research tasks. Early participants were rewarded through staking and launch incentives, with roughly 3% of the total supply, or 99.6 million BIO, distributed to users who staked BNB or FDUSD. The distribution was designed to be fair and community-oriented, with no traditional pre-mine, and additional allocations gradually released according to vesting schedules. This early activation of governance, funding, and staking programs helped Bio Protocol scale its community and establish itself as a decentralized science ecosystem focused on on-chain research, funding, and biotech innovation.

What Are the Key Features of BIO?

A central feature of BIO is its robust governance framework, which empowers token holders to actively participate in decision-making for the Bio Protocol ecosystem. By staking BIO, holders can vote to approve or reject BioDAO proposals, helping determine which biotech projects receive funding and how research priorities are set. This crowd-sourced model decentralizes traditional scientific funding, giving the community real influence over the direction of research and innovation. Another key feature is the BioAgent infrastructure. These on-chain autonomous agents can perform scientific workloads, such as hypothesis testing, data analysis, and milestone verification, allowing researchers to scale complex experiments without relying solely on centralized labs or external funding. The protocol also incorporates a liquidity mechanism: when new BioDAO tokens are launched, they are typically paired with BIO in liquidity pools, incentivizing early participants to provide capital and maintain healthy markets. A portion of protocol fees and rewards is continuously directed back into the BIO treasury, funding future research initiatives and creating a feedback loop that sustains the ecosystem. Finally, BIO supports content and resource curation, enabling stakers to influence how funds, BioAgents, and other ecosystem resources are allocated, which scientific pathways are prioritized, and which projects gain visibility, ensuring the ecosystem evolves in a transparent, community-driven manner.

What Is BIO Used For?

BIO has multiple real-world and on-chain use cases. First, it is used for governance. BIO holders vote on BioDAO grants, research priorities, and treasury allocation. Second, BIO is needed for participation in launch rounds. To invest in new BioDAOs or receive early access, users must stake or commit BIO. Third, BIO powers research automation. It can be used to compensate and incentivize BioAgents to perform tasks like hypothesis testing and data validation. Fourth, BIO acts as liquidity capital. Many BioDAO token sales or liquidity pools are paired with BIO, making it the base asset for many biotech projects. Finally, through its Bio/Acc Rewards program, BIO is distributed to contributors, clinical trial participants, and others who actively engage with the DeSci ecosystem, tying value to real scientific progress.

Bio Protocol Roadmap Highlights

Bio Protocol launched its core infrastructure, including token, DAO, and BioAgents, in early 2025, marking the beginning of on-chain biotech governance. The team has focused on onboarding researcher-led DAOs and funding early-stage biotech initiatives through the BioLaunchpad. In parallel, they are expanding the BioAgent framework to support more complex scientific tasks, including preclinical research and hypothesis generation. Over time, the protocol intends to deepen integration with the broader biotech industry by tokenizing IP, licensing technology, and funding translational research. Future milestones also include cross-chain expansion to bring BIO and BioDAO assets to more networks, supporting a more globalized DeSci ecosystem.

What Is the BIO Token Utility?

BIO is not just a speculative token. It is the governance and utility backbone of the Bio Protocol ecosystem. By staking BIO, users gain voting power to decide which projects receive funding, how the treasury is used, and how IP is managed. It is also used as an economic incentive. Projects pay BIO to BioAgents for scientific work, and contributors earn BIO for research and milestones. For launchpad activities, BIO is required to participate in auctions or early fundraising rounds for BioDAOs. And for liquidity, BIO is frequently paired with new project tokens, ensuring that early-stage biotech DAOs have deep, on-chain markets. These interconnected utilities help align investment, science, and governance in one coherent system.

What Blockchain Does BIO Operate On?

BIO is an ERC-20 token on Ethereum, which ensures compatibility with a wide range of DeFi protocols, governance tools, and wallets. The protocol also supports certain cross-chain activities and assets, but its core token and DAO operations are built on Ethereum. This blockchain choice ensures broad wallet compatibility, mature tooling, and reliable security, while giving decentralized science projects access to the Ethereum ecosystem.

What Are BIO Tokenomics?

The circulating supply of BIO is approximately 1.30 billion tokens, out of a total supply of 3,320,000,000 BIO. According to the protocol’s documentation, 25% of the total supply, or 830 million BIO, is allocated to ecosystem incentives, 21.2% or 703.84 million BIO is reserved for core contributors, and 20% or 664 million BIO is designated for a community auction. Investors receive 13.6% or 451.52 million BIO, while 6% or 199.2 million is allocated for community airdrops. The Molecule ecosystem fund receives 5% or 166 million BIO, another 5% or 166 million is reserved for governance, and 4.2% or 139.44 million is assigned to advisors. There is also a Bio/Acc Rewards pool equivalent to 4% of the supply, or 133 million BIO, designed to incentivize community contributions, data sharing, and milestone achievement. Vesting schedules encourage long-term alignment, with core contributors vesting over six years with a one-year cliff, investors having a one-year cliff plus four-year linear vesting, and advisors vesting over six years. These allocations reflect a model that emphasizes community participation, protocol growth, and sustainable ecosystem development.

How to Securely Store BIO

BIO works with the most popular crypto wallets that support Ethereum-based assets. The easiest way to engage with BIO is through BingX Spot Market where users can buy, sell, and hold tokens securely without managing private keys or additional wallet setups. This method provides exchange-level security, a custodial wallet structure, and seamless access for trading or portfolio management. BIO is also compatible with major self-custody wallets such as MetaMask and Trust Wallet as well as hardware wallets like Ledger all of which support ERC-20 tokens. These wallets give users full control of private keys and allow participation in decentralized applications, staking opportunities, future ecosystem features, and governance activities. By adding the Ethereum network and importing the BIO token through its official contract address, users can securely access the full range of token utilities and benefits.

Is BIO a Good Investment?

BIO is potentially a strong long-term play if you believe in decentralized science. Its tokenomics dedicate 56 % of supply to community incentives and new project funding, creating opportunity for value accrual through research success, IP commercialization, and active DAO governance. However, risks are significant. Scientific projects may fail, governance decisions may not align with financial value, and vesting schedules could put downward pressure on price. Multi-chain deployment adds complexity, and regulatory risk in biotech or tokenized IP may be present. For investors interested in decentralized science, biotech innovation, and on-chain research economies, BIO offers a unique mission-driven asset, but it is not without speculative risk.